FEATURE ARTICLES
Though these challenges can result from equipment, raw material differences, and process variability, operational environments must be a major focus during lab trials, as Yuhei Yamamoto and his team at Takeda learned in a recent experience.
- The Regulatory Imperative To Improve Environmental And Sustainability Stewardship In Biopharma
- Operating And Maintaining Pharmaceutical Gas Distribution Systems
- August 2025 — CDMO Opportunities And Threats Report
- The New FDA Era Of Radical Transparency And Pervasive Oversight
- Building The Biopharma Manufacturing Facility Of The Future Requires A Phased IT/OT Strategy
- 10 Ways To Strengthen U.S. API: Part II
- 10 Ways To Strengthen U.S. API: Part I
PHARMA ONLINE WHITE PAPERS
-
Digital Transformation And Quality By Design For Enhanced Development
Discover how digital transformation and Quality by Design are revolutionizing pharmaceutical development to boost efficiency, enhance compliance, and accelerate innovation across the drug lifecycle.
-
The Complete Flow Cytometry Guide9/24/2024
This guide covers the fundamentals of flow cytometry, aiming to help you better understand how it works, when it is most valuable, and how to conduct an experiment.
-
Revolutionizing Manufacturing For Pharma And Biopharma7/9/2024
Explore the evolution of Industry 4.0 in pharmaceutical manufacturing, the benefits and implications of Smart Factories, and the challenges along the road toward implementing a Smart Factory.
-
Understanding Biosafety Levels5/20/2024
Compliance with biosafety levels (BSLs) is crucial in ensuring that your laboratories meet stringent standards to protect staff and prevent the escape of biological agents.
-
Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge SCID Mouse Models6/10/2025
Advance your RSV therapeutic pipeline with trusted, IND-enabling preclinical services that deliver clinically relevant data through optimized study designs and validated rodent models.
-
Extractables And Leachables: Risk Management And Analytical Solutions10/11/2023
Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.
PHARMA ONLINE APP NOTES & CASE STUDIES
- TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications
- Modelling TPDs Utilizing Computational And Medicinal Chemistry Approaches
- Exosome Isolation By TFF And Size Exclusion Chromatography
- Development Of An Effective LC-MS/MS Cleaning Validation Method
- A Transient Cell Line To Produce rAAV With Low-Level hcDNA Encapsidation
NEWSLETTER ARCHIVE
- 09.18.25 -- How can real-time facility monitoring and biofluorescent particle counting transform aseptic manufacturing?
- 09.18.25 -- STREAM Edition: Mitigation Strategies For HVAC Recirculation
- 09.17.25 -- Pathway To Approval: Analytical Strategies To Support GLP-1 Receptor Agonist Development
- 09.16.25 -- Reimagining the future of aseptic filling
- 09.16.25 -- EMA Issues Revised Annex 11, New Annex 22, And Associated Documents On Data Governance
INDUSTRY NEWS
-
FDA Cracks Down On GLP-1 Imports
GLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
-
Oregon Court Upholds Drug Price Transparency Law
The law was first enacted in 2018, followed by a lawsuit by Pharmaceutical Research and Manufacturers of America (PhRMA) in 2019, claiming an infringement of free speech for pharmaceutical companies and violation of public property. PhRMA asked the court to bar Oregon from enforcing the law.
-
Spray Drying Market Poised To Nearly Double By 2033
The growth of the spray drying market is attributed to demand for enhanced stability, bioavailability and solubility of poorly soluble drugs.
-
AbbVie Enters Psychedelic Market With Bretisilocin Acquisition
Bretisilocin is a next-generation psychedelic compound (5-HT2A receptor agonist and 5-HT releaser) designed to exert a shorter duration of psychoactive experience, while retaining an extended therapeutic benefit
-
J&J Commits $2 Billion To N.C. Manufacturing Facility
J&J’s latest announcement follows its commitment in March to invest $55 billion to support U.S. manufacturing, R&D, and technology over the next four years.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS

The modern microbiology laboratory is starting to look very different from the laboratory of even 10 years ago. The work will be similar, yet technology will have advanced. Automation, in particular, is taking center stage. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
GSK Commits $30B To U.S. R&D And Drug Manufacturing Expansion9/17/2025
GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.
-
Eli Lilly Announces Plans To Build New $5 Billion Drug Manufacturing Facility In Virginia9/17/2025
Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company's first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio.
-
CAI Appoints Jamie Robertson As Vice President Of Mission Critical To Drive Innovation And Operational Excellence Across Global Infrastructure Projects9/14/2025
CAI, a global leader in operational readiness and excellence for high-stakes, regulated environments, is proud to announce the appointment of Jamie Robertson as Vice President of Mission Critical.
-
Körber To Exhibit Aseptic Processing, Packaging, Inspection And MES Software Technologies At Pack Expo 20259/11/2025
Körber, a major international technology group, invites media to visit its booth at Pack Expo 2025 in Las Vegas. This is a unique opportunity to discover how Körber is transforming entrepreneurial thinking into tangible customer success and shaping technological change.
-
Assets Of Sutro Biopharma To Be Auctioned – December 20259/11/2025
Late-model lab R&D and manufacturing equipment surplus to future needs of Sutro biopharma: spray dryer, chromatography systems, Westfalia separators, HPLCs & more.